Skip to main content

Table 1 Clinical characteristics at baseline visit by number of previous bDMARDs

From: Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register

 

Total

Bionaïve

1 previous bDMARD

≥ 2 previous bDMARDs

Number of patients (%)

2716

453 (16.7)

741 (27.3)

1522 (56)

Female sex (%)

2176 (80.1)

325 (71.7)

599 (80.8)

1252 (82.3)

Age at treatment start (years); mean (SD)

59.3 (13.3)

61.7 (14.0)

60.7 (12.9)

57.8 (13.0)

Duration of RA at treatment start (years); mean (SD)

14.2 (11.4)

9.5 (11.1)

14.4 (11.8)

15.5 (10.8)

Intravenous treatment

1365 (50.3%)

194 (42.8%)

381 (51.8%)

790 (52.1%)

Subcutaneous treatment

1338 (49.3%)

257 (57.0%)

355 (48.2%)

726 (47.9%)

ESR (mm 1st h); median (IQR)

23 (11–42)

23 (12–42)

23.5 (12–40.25)

22 (10–41)

CRP (mg/l); median (IQR)

9 (3.5–23)

11 (5–24)

8 (3.48–23)

8 (3–22)

DAS28; mean (SD)

4.98 (1.29)

5.01 (1.23)

4.93 (1.28)

4.99 (1.31)

DAS28-CRP; mean (SD)

4.66 (1.13)

4.64 (1.14)

4.57 (1.13)

4.70 (1.13)

VAS pain (0–100); mean (SD)

60 (23)

58 (24)

59 (23)

62 (22)

VAS global (0–100); mean (SD)

60 (22)

56 (23)

60 (23)

62 (22)

Swollen joint count (0–28); median (IQR)

5 (2–9)

6 (3–10)

5 (2–8)

5 (2–9)

Tender joint count (0–28); median (IQR)

6 (3–10)

6 (2–11)

6 (3–10)

6 (3–11)

HAQ-DI (0–3); mean (SD)

1.32 (0.63)

1.16 (0.63)

1.30 (0.65)

1.37 (0.62)

Physicians global (0–4); median (IQR)

2 (2–3)

2 (2–3)

2 (2–3)

2 (2–3)

Current methotrexate

1288 (57%)

196 (55%)

373 (61%)

719 (55%)

Current glucocorticoids

1316 (49%)

176 (39%)

345 (47%)

795 (52%)

Glucocorticoids dose in mg, prednisolone equivalent; mean (SD)

7.5 (4.2)

7.6 (3.9)

6.9 (4.0)

7.8 (4.3)

Current csDMARD

1489 (55%)

237 (52%)

425 (57%)

827 (54%)

  1. Missing data: Duration of RA at treatment start (years), 17; intravenous/subcutaneous treatment, 13; ESR, 714; CRP, 580; DAS 28, 921; CRP, 811; VAS pain, 748; VAS global, 711; swollen joint count, 624; tender joint count, 625; HAQ-DI, 825; physician global, 711; current methotrexate, 439